IL2 and cancer: The therapeutic potential of NK cells in cancer immunotherapy was firstly highlighted by Miller et al. in 2005, showing that the infusion of short-term IL-2-activated allogeneic haploidentical NK cells induce the remission in patients with refractory leukemia [179].